Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Innate Immunity and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ADAR1/ADAR drug discovery across modalities.
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ADAR1 Recombinant Protein (p150/p110 Isoforms); sequence-verified, >95% purity, Endotoxin <1 EU/µg. | View ADAR1 Products |
| Gene Delivery | ADAR1 Promise-ORF / Lentivirus (full-length p150/p110) for stable cell lines and IFN-reporter assays. | View ADAR1 Products |
| Benchmark Ab | Anti-ADAR1 (pan-isoform recombinant monoclonal) for WB, IP, cellular validation. | View ADAR1 Products |
| Validator | ADAR1 siRNA Set for knockdown verification and specificity controls. | View ADAR1 Products |
| Related Target A | ADAR2 (ADARB1) – family homolog for selectivity counter-screen; essential to avoid neurotoxicity. | View ADAR2 Products |
| Related Target B | STING1 (TMEM173) – downstream innate immunity node activated upon ADAR1 inhibition. | View STING1 Products |
| Related Target C | IFIH1 (MDA5) – dsRNA sensor that triggers type I IFN upon ADAR1 loss. | View IFIH1 Products |
| Related Target D | DDX58 (RIG-I) – parallel dsRNA sensor for synthetic lethality axis evaluation. | View DDX58 Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform-specific inhibition (p150 vs p110) | Distinct recombinant constructs for interferon-inducible p150 (with Zα domain) and constitutive p110, sequence-verified. |
| Selectivity over ADAR2/ADAR3 (avoid neurotoxicity) | ADAR2 homolog panel >95% purity, mass-spec verified; ADAR3 available on request. |
| Enzymatic activity quantification | High-purity catalytic domain (deaminase) with confirmed dsRNA binding; theoretical MW verified. |
| Cellular RNA editing validation | ADAR1 ORF lentivirus and validated siRNA for gain/loss-of-function in reporter cell lines. |
| False-positive control in binding assays | Endotoxin-controlled (<1 EU/µg) proteins; dsRNA-substrate compatible formats. |
Live ADAR1/ADAR R&D Tracker
Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The ADAR1 therapeutic race is intensifying, driven by its central role in innate immune suppression via A-to-I RNA editing. First-generation small-molecule inhibitors and targeted protein degraders (PROTACs) are entering preclinical optimization, with key players like Accent Therapeutics leading. The next wave focuses on combination strategies (e.g., with PD-1/PD-L1 or STING agonists) and isoform-selective (p150 vs p110) approaches to mitigate neurotoxicity from ADAR2 cross-reactivity and autoimmune toxicity. Synthetic lethality with STING-deficient tumors and ATM/DDR-defective cancers is also emerging as a differentiated strategy.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Accent Therapeutics, Emerging Biotechs, Large Pharma | Solid Tumors (IO combo, STING activation) | Enzymatic assay with high-purity deaminase domain; selectivity panel vs ADAR2 required (>100-fold). |
| PROTAC / Targeted Degrader | Specialized Biotechs, Early-stage Programs | Immunotherapy-resistant cancers (refractory) | Full-length ADAR1 p150 with Zα domain for ternary complex formation; cellular degradation validation. |
| RNA Therapeutics (siRNA/ASO / Endogenous Editing) | Korro Bio, ProQR, RNA Therapeutics Companies | Genetic diseases, viral infections; also used as tools for target validation | Target engagement assay (need lentivirus for precise cell models); specificity validation vs ADAR2. |
| Synthetic Lethality & Isoform-Selective Modulator | Precision Medicine Biotechs, Oncology Translational Labs | STING-deficient tumors (colorectal, lung, breast); neurological disorders | Dual-cellular assay: ADAR1 lentivirus rescue + STING1/IFIH1 reporter lines; isoform-specific Z-RNA binding assay. |
Key Mutations & Resistance Insights
Fact-payload mutations (dbSNP:rs1466731, AGS6 rs145588689, rs2229857) highlight potential resistance hotspots in the catalytic domain and dsRBD. TarMart offers custom mutant proteins (e.g., E396A, R892A) for structural biology and resistance mechanism studies to support lead optimization.